$ADIL
ADIAL PHARMACEUTICALS, INC. Stock $adil

$adil Overview Financials Valuation SEC Filings Company Website

2022 Q4 Form 10-Q Financial Statement

#000121390022071643 Filed on November 14, 2022

Income Statement

Concept	2022 Q4	2022 Q3	2021 Q3
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$2.103M	$1.944M	$2.372M
YoY Change	0.17%	-18.03%	59.18%
% of Gross Profit
Research & Development	$1.137M	$1.244M	$1.692M
YoY Change	-51.27%	-26.49%	-8.56%
% of Gross Profit
Depreciation & Amortization	$2.080K	$2.070K	$140.00
YoY Change	-48.26%	1378.57%
% of Gross Profit
Operating Expenses	$3.240M	$3.188M	$4.064M
YoY Change	-26.91%	-21.55%	21.66%
Operating Profit		-$3.188M	-$4.064M
YoY Change		-21.55%
Interest Expense	$47.82K	$3.340K	$2.860K
YoY Change	2073.64%	16.78%
% of Operating Profit
Other Income/Expense, Net	$325.0K	$78.34K	-$257.1K
YoY Change	501.74%	-130.47%
Pretax Income	-$2.867M	-$3.109M	-$4.318M
YoY Change	-51.61%	-27.99%	29.27%
Income Tax	-$500.00		$0.00
% Of Pretax Income
Net Earnings	-$2.867M	-$3.109M	-$4.318M
YoY Change	-50.84%	-27.99%	29.27%
Net Earnings / Revenue
Basic Earnings Per Share		-$0.12	-$0.22
Diluted Earnings Per Share	-$0.11	-$0.12	-$217.5K
COMMON SHARES
Basic Shares Outstanding	26.85M shares	25.85M shares	19.85M shares
Diluted Shares Outstanding		25.72M shares	19.85M shares

Balance Sheet

Concept	2022 Q4	2022 Q3	2021 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$4.002M	$5.753M	$7.180M
YoY Change	-33.99%	-19.88%	-2.58%
Cash & Equivalents	$4.002M	$5.753M	$7.180M
Short-Term Investments
Other Short-Term Assets	$778.1K	$1.021M	$805.3K
YoY Change	94.81%	26.73%	-0.58%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$4.780M	$6.773M	$7.986M
YoY Change	-26.03%	-15.18%	-2.26%
LONG-TERM ASSETS
Property, Plant & Equipment	$50.42K	$52.36K	$320.6K
YoY Change	-13.28%	-83.67%
Goodwill	$249.0K	$249.0K
YoY Change	0.0%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$952.9K	$968.4K	$2.461M
YoY Change	-5.97%	-60.64%	24506.8%
TOTAL ASSETS
Total Short-Term Assets	$4.780M	$6.773M	$7.986M
Total Long-Term Assets	$952.9K	$968.4K	$2.461M
Total Assets	$5.733M	$7.742M	$10.45M
YoY Change	-23.31%	-25.89%	27.7%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$393.8K	$278.2K	$185.2K
YoY Change	37.61%	50.22%	-25.92%
Accrued Expenses	$1.155M	$955.4K	$1.773M
YoY Change	-51.42%	-46.1%	108.55%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$1.791M	$1.327M	$1.958M
YoY Change	-34.22%	-32.22%	79.62%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$642.6K	$982.3K	$1.288M
YoY Change	-47.39%	-23.75%
Total Long-Term Liabilities	$642.6K	$982.3K	$1.288M
YoY Change	-47.39%	-23.75%
TOTAL LIABILITIES
Total Short-Term Liabilities	$1.791M	$1.327M	$1.958M
Total Long-Term Liabilities	$642.6K	$982.3K	$1.288M
Total Liabilities	$2.456M	$2.333M	$3.246M
YoY Change	-38.08%	-28.14%	197.81%
SHAREHOLDERS EQUITY
Retained Earnings	-$63.67M	-$60.81M
YoY Change	24.99%
Common Stock	$26.69K	$26.85K
YoY Change	27.4%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$3.276M	$5.409M	$7.200M
YoY Change
Total Liabilities & Shareholders Equity	$5.733M	$7.742M	$10.45M
YoY Change	-23.31%	-25.89%	27.7%

Cashflow Statement

Concept	2022 Q4	2022 Q3	2021 Q3
OPERATING ACTIVITIES
Net Income	-$2.867M	-$3.109M	-$4.318M
YoY Change	-50.84%	-27.99%	29.27%
Depreciation, Depletion And Amortization	$2.080K	$2.070K	$140.00
YoY Change	-48.26%	1378.57%
Cash From Operating Activities	-$1.751M	-$3.404M	-$3.530M
YoY Change	-26.22%	-3.56%	59.71%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	$0.00	$0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities	$0.00	$0.00	$0.00
YoY Change
Cash From Investing Activities	$0.00	$0.00	$0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$5.500M
YoY Change			478.95%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	0.000	0.000	5.500M
YoY Change	-100.0%	-100.0%	478.95%
NET CHANGE
Cash From Operating Activities	-1.751M	-3.404M	-3.530M
Cash From Investing Activities	0.000	0.000	0.000
Cash From Financing Activities	0.000	0.000	5.500M
Net Change In Cash	-1.751M	-3.404M	1.970M
YoY Change	56.6%	-272.76%	-256.38%
FREE CASH FLOW
Cash From Operating Activities	-$1.751M	-$3.404M	-$3.530M
Capital Expenditures	$0.00	$0.00	$0.00
Free Cash Flow	-$1.751M	-$3.404M	-$3.530M
YoY Change	-26.22%	-3.56%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	us-gaap	Other Income OtherIncome		usd
CY2022Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2021Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	24803909	shares
CY2022Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	25724557	shares
	us-gaap	Short Term Lease Cost ShortTermLeaseCost		usd
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2022-09-30
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-38323
	dei	Entity Registrant Name EntityRegistrantName	ADIAL PHARMACEUTICALS, INC.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	82-3074668
	dei	Entity Address Address Line1 EntityAddressAddressLine1	1180 Seminole Trail
	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 495
	dei	Entity Address City Or Town EntityAddressCityOrTown	Charlottesville
	dei	Entity Address State Or Province EntityAddressStateOrProvince	VA
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	22901
	dei	City Area Code CityAreaCode	(434)
	dei	Local Phone Number LocalPhoneNumber	422-9800
	dei	Security12b Title Security12bTitle	Common Stock
	dei	Trading Symbol TradingSymbol	ADIL
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
	dei	Entity Shell Company EntityShellCompany	false
CY2022Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	26853962	shares
CY2022Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	5752665	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	6062173	usd
CY2022Q3	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	516500	usd
CY2021Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	9931	usd
CY2022Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	504104	usd
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	389501	usd
CY2022Q3	us-gaap	Assets Current AssetsCurrent	6773269	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	6461605	usd
CY2022Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	52355	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	58149	usd
CY2022Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	4618	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	5041	usd
CY2022Q3	adil	Acquired Inprocess Research And Development AcquiredInprocessResearchAndDevelopment	455000	usd
CY2021Q4	adil	Acquired Inprocess Research And Development AcquiredInprocessResearchAndDevelopment	455000	usd
CY2022Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	207471	usd
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	246209	usd
CY2022Q3	us-gaap	Goodwill Goodwill	248971	usd
CY2021Q4	us-gaap	Goodwill Goodwill	248971	usd
CY2022Q3	us-gaap	Assets Assets	7741684	usd
CY2021Q4	us-gaap	Assets Assets	7474975	usd
CY2022Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	278200	usd
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	286192	usd
CY2022Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	955405	usd
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2376930	usd
CY2022Q3	us-gaap	Accounts Payable Related Parties Current AccountsPayableRelatedPartiesCurrent	30000	usd
CY2022Q3	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	54961	usd
CY2021Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	49585	usd
CY2022Q3	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	8386	usd
CY2021Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	9683	usd
CY2022Q3	us-gaap	Liabilities Current LiabilitiesCurrent	1326952	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	2722390	usd
CY2022Q3	us-gaap	Capital Lease Obligations Noncurrent CapitalLeaseObligationsNoncurrent	817000	usd
CY2021Q4	us-gaap	Capital Lease Obligations Noncurrent CapitalLeaseObligationsNoncurrent	1014000	usd
CY2022Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	165288	usd
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	207375	usd
CY2022Q3	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	23399	usd
CY2021Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	23399	usd
CY2022Q3	us-gaap	Liabilities Liabilities	2332639	usd
CY2021Q4	us-gaap	Liabilities Liabilities	3967164	usd
CY2022Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2022Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000	shares
CY2022Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	26853962	shares
CY2022Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	26853962	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	20946712	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	20946712	shares
CY2022Q3	us-gaap	Common Stock Value CommonStockValue	26854	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	20947	usd
CY2022Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	66190027	usd
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	54429979	usd
CY2022Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-60807836	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-50943115	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	5409045	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	3507811	usd
CY2022Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	7741684	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	7474975	usd
CY2022Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1243556	usd
CY2021Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1691688	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3040024	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	6062360	usd
CY2022Q3	us-gaap	Asset Impairment Charges AssetImpairmentCharges	1944137	usd
CY2021Q3	us-gaap	Asset Impairment Charges AssetImpairmentCharges	2371840	usd
	us-gaap	Asset Impairment Charges AssetImpairmentCharges	7037085	usd
	us-gaap	Asset Impairment Charges AssetImpairmentCharges	7245227	usd
CY2022Q3	us-gaap	Operating Expenses OperatingExpenses	3187693	usd
CY2021Q3	us-gaap	Operating Expenses OperatingExpenses	4063528	usd
	us-gaap	Operating Expenses OperatingExpenses	10077109	usd
	us-gaap	Operating Expenses OperatingExpenses	13307587	usd
CY2022Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-3187693	usd
CY2021Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-4063528	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-10077109	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-13307587	usd
CY2022Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	3343	usd
CY2021Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	2862	usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest	15388	usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest	4338	usd
CY2022Q3	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	75000	usd
CY2021Q3	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	-274524	usd
	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	197000	usd
	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	-335727	usd
CY2021Q3	us-gaap	Other Income OtherIncome	17406	usd
	us-gaap	Other Income OtherIncome	46494	usd
CY2022Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.12
CY2022Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	78343	usd
CY2021Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-254256	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	212388	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-284895	usd
CY2022Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-3109350	usd
CY2021Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-4317784	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-9864721	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-13592482	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-3109350	usd
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-4317784	usd
	us-gaap	Net Income Loss NetIncomeLoss	-9864721	usd
	us-gaap	Net Income Loss NetIncomeLoss	-13592482	usd
CY2022Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.12
CY2021Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.22
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.4
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.76
CY2022Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	25724557	shares
CY2021Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	19848108	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	24803909	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	17864604	shares
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	3507811	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	567189	usd
CY2022Q1	adil	Equitybased Compensation Stock Issuances To Consultants And Employees EquitybasedCompensationStockIssuancesToConsultantsAndEmployees	416423	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	9123741	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-2907839	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	10707325	usd
CY2022Q2	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	625816	usd
CY2022Q2	adil	Equitybased Compensation Stock Issuances To Consultants And Employees EquitybasedCompensationStockIssuancesToConsultantsAndEmployees	473906	usd
CY2022Q2	adil	Stock Issued During Period Value Warrants Exercised StockIssuedDuringPeriodValueWarrantsExercised	1865	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-3847532	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	7961380	usd
CY2022Q3	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	477868	usd
CY2022Q3	adil	Equitybased Compensation Stock Issuances To Consultants And Employees EquitybasedCompensationStockIssuancesToConsultantsAndEmployees	79147	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-3109350	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	5409045	usd
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	3986066	usd
CY2021Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	473787	usd
CY2021Q1	adil	Equitybased Compensation Stock Issuances To Consultants And Employees EquitybasedCompensationStockIssuancesToConsultantsAndEmployees	850900	usd
CY2021Q1	adil	Stock Issued During Period Value Warrants Exercised StockIssuedDuringPeriodValueWarrantsExercised	1425000	usd
CY2021Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	14500	usd
CY2021Q1	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	1060150	usd
CY2021Q1	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	2641003	usd
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-4833764	usd
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	5617642	usd
CY2021Q2	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	568295	usd
CY2021Q2	adil	Equitybased Compensation Stock Issuances To Consultants And Employees EquitybasedCompensationStockIssuancesToConsultantsAndEmployees	275000	usd
CY2021Q2	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	2809000	usd
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-4440934	usd
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	4829003	usd
CY2021Q3	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	640777	usd
CY2021Q3	adil	Equitybased Compensation Stock Issuances To Consultants And Employees EquitybasedCompensationStockIssuancesToConsultantsAndEmployees	548100	usd
CY2021Q3	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	5500002	usd
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-4317784	usd
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	7200098	usd
	us-gaap	Net Income Loss NetIncomeLoss	-9864721	usd
	us-gaap	Net Income Loss NetIncomeLoss	-13592482	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	2640349	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	3356859	usd
	us-gaap	Gains Losses On Restructuring Of Debt GainsLossesOnRestructuringOfDebt	29088	usd
	us-gaap	Other Depreciation And Amortization OtherDepreciationAndAmortization	5794	usd
	us-gaap	Other Depreciation And Amortization OtherDepreciationAndAmortization	2593	usd
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	6954	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	423	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	423	usd
	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	38738	usd
	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	35700	usd
	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	197000	usd
	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	-335727	usd
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	506569	usd
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	2500	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	114603	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	68095	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-1421525	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	868200	usd
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	30000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-9289	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-464459	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-36711	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-26229	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-9435114	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-9576397	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	64605	usd
	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	-30589	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-34016	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	9123741	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	10950005	usd
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	1865	usd
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	1425000	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	14500	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	9125606	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	12389505	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-309508	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	2779092	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	6062173	usd
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	4401114	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	5752665	usd
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	7180206	usd
	adil	Reclassification Of Stockbased Comp From Accrued Expenses ReclassificationOfStockbasedCompFromAccruedExpenses	1060150	usd
	adil	Noncash Cost Of Commitment Shares NoncashCostOfCommitmentShares	732287	usd
CY2022Q3	adil	Accumulated Deficit AccumulatedDeficit	-60800000	usd
	us-gaap	Use Of Estimates UseOfEstimates	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Use of Estimates</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The preparation of unaudited condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and disclosure of contingent liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Significant items subject to such estimates and assumptions include the valuation of stock-based compensation, accruals associated with third party providers supporting clinical trials, estimated fair values of long-lived assets used to record impairment charges related to intangible assets, acquired in-process research and development (“IPR&D”) and goodwill, allocation of purchase price in business acquisitions, measurement of contingent liabilities, and income tax asset realization. In particular, the recognition of clinical trial costs is dependent on the Company’s own judgement, as well as the judgment of our contractors and subcontractors in their reporting of information to us.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt"> </p>
	adil	Warrants To Purchase Common Shares WarrantsToPurchaseCommonShares	12095870	shares
	adil	Warrants To Purchase Common Shares WarrantsToPurchaseCommonShares	7884936	shares
	adil	Common Shares Issuable On Exercise Of Options CommonSharesIssuableOnExerciseOfOptions	4316977	shares
	adil	Common Shares Issuable On Exercise Of Options CommonSharesIssuableOnExerciseOfOptions	3670866	shares
	us-gaap	Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation	1194444	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	17607291	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	11555802	shares
CY2022Q3	us-gaap	Percentage Of Weighted Average Cost Inventory PercentageOfWeightedAverageCostInventory	0.44	pure
CY2021Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	1014000	usd
	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Gain Loss Included In Other Comprehensive Income Loss FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss	197000	usd
CY2022Q3	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	817000	usd
CY2022Q3	adil	Clinical Research Organization Services And Expenses ClinicalResearchOrganizationServicesAndExpenses	117127	usd
CY2021Q4	adil	Clinical Research Organization Services And Expenses ClinicalResearchOrganizationServicesAndExpenses	1826479	usd
CY2022Q3	us-gaap	Workers Compensation Liability Current WorkersCompensationLiabilityCurrent	686501	usd
CY2021Q4	us-gaap	Workers Compensation Liability Current WorkersCompensationLiabilityCurrent	520795	usd
CY2022Q3	adil	Manufacturing Expenses ManufacturingExpenses	-119839	usd
CY2022Q3	adil	Legal And Consulting Services LegalAndConsultingServices	31938	usd
CY2021Q4	adil	Legal And Consulting Services LegalAndConsultingServices	29656	usd
CY2022Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	955405	usd
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2376930	usd
CY2020Q4	adil	Membership Interest Description MembershipInterestDescription	Mr. Stilley owned approximately 28.7% of the membership interest of Purnovate and Mr. Newman controlled two entities that, together, own less than 1% of the membership interests of Purnovate. As a result of the foregoing, the Company formed a Special Committee of independent members of its Board of Directors to review and negotiate the acquisition terms.
CY2021Q1	adil	Securities Purchase Agreements Description SecuritiesPurchaseAgreementsDescription	On March 11, 2021, the Company entered into Securities Purchase Agreements (the “March 2021 SPAs”) with each of Bespoke, three entities controlled by Mr. Newman, and Keystone Capital Partners, LLC (“Keystone”), pursuant to which: (i) Bespoke Growth Partners, Inc. (“Bespoke”) a company controlled by Mark Peikin, the Company’s Chief Strategy Officer who is not an executive officer, agreed to purchase an aggregate of 336,667 shares of the Company’s common stock at a purchase price of $3.00 per share for aggregate gross proceeds of $1,010,001; (ii) Mr. Newman agreed to purchase an aggregate of 30,000 shares of the Company’s common stock at a purchase price of $3.00 per share for aggregate gross proceeds of $90,000; and (iii) Keystone agreed to purchase an aggregate of 333,334 shares of the Company’s common stock at a purchase price of $3.00 per share for aggregate gross proceeds of $1,000,002. During the year ended December 31, 2021, the Company issued an aggregate of 700,001 shares of common stock to such individuals for total proceeds of $2,100,003. The shares sold pursuant to the March 2021 SPAs were registered pursuant to a registration statement on Form S-3 that was filed with the SEC on April 20, 2021 and declared effective on May 26, 2021.
CY2021Q3	adil	Securities Purchase Agreements Description SecuritiesPurchaseAgreementsDescription	On July 6, 2021, the Company entered into Securities Purchase Agreements, dated July 6, 2021 (the “June 2021 SPAs”), with three pre-existing investors for an aggregate investment of $5,000,004 in consideration of the purchase by such investors of an aggregate of 1,666,667 shares of the Company’s common stock at a purchase price of $3.00 per share. June 2021 SPAs were entered with each of Bespoke , Keystone, and Richard Gilliam, a private investor (“Gilliam”) (collectively, the “Investors,” and each an “Investor”), pursuant to which: (i) Bespoke agreed to purchase an aggregate of 833,334 shares of the Company’s common stock at a purchase price of $3.00 per share for aggregate gross proceeds of $2,500,002; (ii) Keystone agreed to purchase an aggregate of 500,000 shares of the Company’s common stock at a purchase price of $3.00 per share for aggregate gross proceeds of $1,500,000; and (iii) Gilliam agreed to purchase an aggregate of 333,334 shares of the Company’s common stock at a purchase price of $3.00 per share for gross proceeds of $1,000,002.
CY2022Q1	adil	Common Stock Issuances CommonStockIssuances	On February 10, 2022, the Company, entered into a securities purchase agreement with an accredited institutional investor (“the Investor”) providing for the issuance of (i) 2,322,250 shares of the Company’s common stock, par value $0.001, (ii) pre-funded warrants to purchase up to 1,865,000 shares of common stock with an exercise price of $0.001 per share, which Pre-Funded Warrants are to be issued in lieu of shares of common stock to ensure that the Investor does not exceed certain beneficial ownership limitations, and (iii) warrants, with a term of five years and six months from the date of issuance, to purchase an aggregate of up to 3,977,888 shares of common stock at an exercise price of $2.52 per share.
CY2022Q1	us-gaap	Proceeds From Debt Net Of Issuance Costs ProceedsFromDebtNetOfIssuanceCosts	9123741	usd
CY2022Q1	us-gaap	Deferred Tax Expense From Stock Options Exercised DeferredTaxExpenseFromStockOptionsExercised	1865	usd
CY2022Q1	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	1865000	shares
CY2022Q3	adil	Stock Issued During Period Shares Other1 StockIssuedDuringPeriodSharesOther1	470000	shares
	us-gaap	Dividends Common Stock Stock DividendsCommonStockStock	818350	usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Rights ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights	During the nine months ended September 30, 2022, the Company issued employees 1,250,000 shares of common stock as bonuses. The first issuance of 250,000 shares are subject to forfeiture for nominal consideration to Company on termination of the employee, the shares no longer being liable to forfeiture (“vesting”) on the following schedule: 1/24 of 166,667 shares vesting on the date of issue and the first of each of the next twenty-three subsequent months, and 83,333 shares vesting on the third anniversary of the date of issue. The second issuance of 1,000,000 shares are subject to forfeiture on the same conditions, but on the following schedule: 1/6 of the issued shares vesting six months from date of issue, then 1/12 vesting at the end of each subsequent three month period, the entire grant being vested three years from date of issue. On September 30, 2022, 55,556 shares were vested and 1,194,444 shares remained subject to repurchase.
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	0	usd
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Shares Purchased For Award ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward	731667	shares
	adil	Weighted Averages Fair Value WeightedAveragesFairValue	1017095	usd
	adil	Weighted Average Fair Values Per Share WeightedAverageFairValuesPerShare	1.39
	adil	Unrecognized Compensation Expense UnrecognizedCompensationExpense	2374688	usd
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P1Y9M18D
CY2022Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	557015	usd
CY2021Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1188877	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2640349	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3356859	usd
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	7990271	shares
	adil	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Terms SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms	P2Y7M17D
CY2021Q4	adil	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercises Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisesPrice	4.82
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue	0.14
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted	6042888	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.74
	adil	Stock Issued During Period Shares Stock Options Exercised1 StockIssuedDuringPeriodSharesStockOptionsExercised1	1865000	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0.001
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	12168159	shares
	adil	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm	P3Y3M14D
CY2022Q3	adil	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercises Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisesPrice	4.03
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue	0.01
	adil	License Fees And Milestone Payments Description LicenseFeesAndMilestonePaymentsDescription	More specifically, the Company paid UVA LVG a license issue fee and is obligated to pay UVA LVG (i) annual minimum royalties of $40,000 commencing in 2017; (ii) a $20,000 milestone payments upon dosing the first patient under a Phase 3 human clinical trial of a licensed product, $155,000 upon the earlier of the completion of a Phase 3 trial of a licensed product, partnering of a licensed product, or sale of the Company, $275,000 upon acceptance of an NDA by the FDA, and $1,000,000 upon approval for sale of AD04 in the U.S., Europe or Japan; as well as (iii) royalties equal to a 2% and 1% of net sales of licensed products in countries in which a valid patent exists or does not exist, respectively, with royalties paid quarterly. In the event of a sublicense to a third party, the Company is obligated to pay royalties to UVA LVG equal to a percentage of what the Company would have been required to pay to UVA LVG had it sold the products under sublicense ourselves. In addition, the Company is required to pay to UVA LVG 15% of any sublicensing income.
CY2022Q3	us-gaap	Royalty Expense RoyaltyExpense	10000	usd
CY2021Q3	us-gaap	Royalty Expense RoyaltyExpense	10000	usd
	us-gaap	Royalty Expense RoyaltyExpense	30000	usd
	us-gaap	Royalty Expense RoyaltyExpense	30000	usd
CY2022Q2	adil	Accrued License Royalty Expense AccruedLicenseRoyaltyExpense	155000	usd
CY2022Q3	us-gaap	Accounts Payable Related Parties Current And Noncurrent AccountsPayableRelatedPartiesCurrentAndNoncurrent	30000	usd
CY2021Q4	us-gaap	Accounts Payable Related Parties Current And Noncurrent AccountsPayableRelatedPartiesCurrentAndNoncurrent	0	usd
CY2018Q4	adil	Master Services Agreement Description MasterServicesAgreementDescription	The MSA has a term of five years, automatically renewed for two-year periods, unless either party gives written notice of a decision not to renew the agreement six months prior to automatic renewal.
CY2018Q4	adil	Service Agreement Description ServiceAgreementDescription	the Company and Crown entered into Service Agreement 1 under the MSA for a 24 week, multi-centered, randomized, double-blind, placebo-controlled, parallel-group, Phase 3 clinical study of AD04 for fees, as amended, of $3,100,764 (€3,168,895 converted to dollars at the Euro/US Dollar exchange rate of 0.9785 $/€ as of September 30, 2022), payable upon attainment of certain milestones.
CY2022Q1	adil	Service Agreement Description ServiceAgreementDescription	the Company acknowledged the occurrence of the milestone event of 90% of trial case report forms having been monitored, and made a payment of $148,875. On May 13, 2022, the Company acknowledged the milestone event of the last patient having made the last clinical visit and made a payment of $146,765, and on June 30, 2022 the Company acknowledged the additional milestone event of the trial database being locked at which time it recognized a payable of $137,375.
CY2022Q2	us-gaap	Life Settlement Contracts Investment Method Carrying Amount LifeSettlementContractsInvestmentMethodCarryingAmount	454034	usd
CY2022Q2	us-gaap	Life Settlement Contracts Investment Method Carrying Amount LifeSettlementContractsInvestmentMethodCarryingAmount	410000	eur
CY2021Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.22
	us-gaap	Other Noncash Income OtherNoncashIncome	275516	usd
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	75319	usd
CY2021Q1	us-gaap	Subordinated Borrowing Interest Rate SubordinatedBorrowingInterestRate	0.09	pure
CY2022Q3	us-gaap	Operating Lease Expense OperatingLeaseExpense	19634	usd
CY2021Q3	us-gaap	Operating Lease Expense OperatingLeaseExpense	22231	usd
	us-gaap	Operating Lease Expense OperatingLeaseExpense	60490	usd
	us-gaap	Operating Lease Expense OperatingLeaseExpense	56090	usd
CY2022Q3	us-gaap	Lease Cost LeaseCost	19634	usd
CY2021Q3	us-gaap	Lease Cost LeaseCost	22231	usd
	us-gaap	Lease Cost LeaseCost	60490	usd
	us-gaap	Lease Cost LeaseCost	56090	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	52595	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	45146	usd
	adil	Supplemental Noncash Amounts Of Lease Liabilities Arising From Obtaining Right Of Use Assets SupplementalNoncashAmountsOfLeaseLiabilitiesArisingFromObtainingRightOfUseAssets	7895	usd
	adil	Supplemental Noncash Amounts Of Lease Liabilities Arising From Obtaining Right Of Use Assets SupplementalNoncashAmountsOfLeaseLiabilitiesArisingFromObtainingRightOfUseAssets	294294	usd
CY2022Q3	adil	Lease Right Of Use Assets LeaseRightOfUseAssets	207471	usd
CY2021Q4	adil	Lease Right Of Use Assets LeaseRightOfUseAssets	246209	usd
CY2022Q3	adil	Total Lease Assets TotalLeaseAssets	207471	usd
CY2021Q4	adil	Total Lease Assets TotalLeaseAssets	246209	usd
CY2022Q3	adil	Lease Liability Current Portion LeaseLiabilityCurrentPortion	54961	usd
CY2021Q4	adil	Lease Liability Current Portion LeaseLiabilityCurrentPortion	49585	usd
CY2022Q3	adil	Lease Liability Net Of Current Portion LeaseLiabilityNetOfCurrentPortion	165288	usd
CY2021Q4	adil	Lease Liability Net Of Current Portion LeaseLiabilityNetOfCurrentPortion	207375	usd
CY2022Q3	adil	Total Lease Liability TotalLeaseLiability	220249	usd
CY2021Q4	adil	Total Lease Liability TotalLeaseLiability	256960	usd
CY2022Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P3Y3M29D
CY2021Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P4Y3M29D
CY2022Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.09	pure
CY2021Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.09	pure
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due Next Rolling Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths	17383	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due In Rolling Year Two LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo	72687	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due In Rolling Year Three LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree	75231	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due In Rolling Year Four LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour	77864	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	6508	usd
CY2022Q3	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	249673	usd
CY2022Q3	adil	Operating Leases Future Minimum Payments Less Effects Of Discounting OperatingLeasesFutureMinimumPaymentsLessEffectsOfDiscounting	-29424	usd
CY2022Q3	us-gaap	Capital Leases Future Minimum Payments Present Value Of Net Minimum Payments CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments	220249	usd
CY2020Q1	adil	Lease Commitments Related Party Description LeaseCommitmentsRelatedPartyDescription	the Company entered into a sublease with Purnovate, LLC, a private company in which the Company’s then CEO had a 28.7% equity interest, for the lease of three offices at 1180 Seminole Trail, Suite 495, Charlottesville, VA 22901. The lease had a term of two years, and the monthly rent was $1,400
CY2021Q3	us-gaap	Operating Leases Rent Expense Sublease Rentals1 OperatingLeasesRentExpenseSubleaseRentals1	1400	usd
	us-gaap	Operating Leases Rent Expense Sublease Rentals1 OperatingLeasesRentExpenseSubleaseRentals1	1400	usd
CY2019Q1	adil	Consulting Agreement Description ConsultingAgreementDescription	the Company entered into a consulting agreement (the “Consulting Agreement”) with Dr. Bankole A. Johnson, who at the time of the agreement was serving as the Chairman of the Board of Directors, for his service as Chief Medical Officer of the Company. The Consulting Agreement has a term of three years, unless terminated by mutual consent or by the Company for cause, which term was extended on March 22, 2022 for an additional three years commencing as of March 24, 2022. Dr. Johnson resigned as Chairman of the Board of Directors at the time of execution of the consulting agreement. Under the terms of the Consulting Agreement, Dr. Johnson’s annual fee of $375,000 per year is paid twice per month. The Consulting Agreement had an expiration date of March 31, 2022, which was extended on March 22, 2022 for an additional three years commencing as of March 24, 2022. On September 8, 2022, the Consulting Agreement was amended to increase Dr. Johnson’s annual fee to $435,000 and to establish a series of payments in cash and stock for the performance of certain milestones. The Company recognized $103,750 and $291,250 in compensation expense in the both the three and nine months ended September 30, 2022 and 2021, respectively, as a result of this agreement.
CY2019Q3	us-gaap	Deferred Compensation Arrangement With Individual Distribution Paid DeferredCompensationArrangementWithIndividualDistributionPaid	300000	usd
	us-gaap	Long Term Purchase Commitment Specified Form Of Payment LongTermPurchaseCommitmentSpecifiedFormOfPayment	$1,409,000
	adil	Advance Payment AdvancePayment	579000	usd
	us-gaap	Other Expenses OtherExpenses	62500	usd
CY2022Q3	adil	Future Cash FutureCash	900000	usd
	us-gaap	Interest Paid Net InterestPaidNet		usd
	us-gaap	Interest Paid Net InterestPaidNet		usd
	us-gaap	Income Taxes Paid IncomeTaxesPaid		usd
	us-gaap	Income Taxes Paid IncomeTaxesPaid		usd
	adil	Reclassification Of Stockbased Comp From Accrued Expenses ReclassificationOfStockbasedCompFromAccruedExpenses		usd
	adil	Noncash Cost Of Commitment Shares NoncashCostOfCommitmentShares		usd
	us-gaap	Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation		shares
CY2021Q4	adil	Manufacturing Expenses ManufacturingExpenses		usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Payments ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments		usd
CY2022Q3	us-gaap	Short Term Lease Cost ShortTermLeaseCost		usd
CY2021Q3	us-gaap	Short Term Lease Cost ShortTermLeaseCost		usd
	us-gaap	Short Term Lease Cost ShortTermLeaseCost		usd
CY2022Q3	us-gaap	Lessee Operating Lease Remaining Lease Term LesseeOperatingLeaseRemainingLeaseTerm	P5Y
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.40
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.76
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	17864604	shares
CY2021Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	19848108	shares
	us-gaap	Gains Losses On Restructuring Of Debt GainsLossesOnRestructuringOfDebt		usd
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit		usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment		usd
	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired		usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities		usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised		usd
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
	dei	Entity Central Index Key EntityCentralIndexKey	0001513525

Files In Submission

Name	View Source	Status
0001213900-22-071643-index-headers.html	Edgar Link	pending
0001213900-22-071643-index.html	Edgar Link	pending
0001213900-22-071643.txt	Edgar Link	pending
0001213900-22-071643-xbrl.zip	Edgar Link	pending
adil-20220930.xsd	Edgar Link	pending
adil-20220930_def.xml	Edgar Link	unprocessable
adil-20220930_cal.xml	Edgar Link	unprocessable
f10q0922ex31-1_adialpharm.htm	Edgar Link	pending
f10q0922ex31-2_adialpharm.htm	Edgar Link	pending
f10q0922ex32-1_adialpharm.htm	Edgar Link	pending
f10q0922ex32-2_adialpharm.htm	Edgar Link	pending
f10q0922_adialpharm.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
adil-20220930_lab.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
adil-20220930_pre.xml	Edgar Link	unprocessable
f10q0922_adialpharm_htm.xml	Edgar Link	completed

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ADIL
ADIAL PHARMACEUTICALS, INC. Stock $adil

2022 Q4 Form 10-Q Financial Statement

#000121390022071643 Filed on November 14, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ADIL ADIAL PHARMACEUTICALS, INC. Stock $adil

2022 Q4 Form 10-Q Financial Statement

#000121390022071643 Filed on November 14, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ADIL
ADIAL PHARMACEUTICALS, INC. Stock $adil